Pharma News

Top 10 most read GaBI Online articles in 2021

Home/Pharma News | Posted 28/01/2022

A review of the Top 10 most read articles reveals that biosimilars are still of most interest to readers. Some of the most memorable events for biosimilars in 2021 were recommendations for biosimilar approvals by the European Medicines Agency (EMA) and by China’s National Medical Products Administration (NMPA), formerly the China Food and Drug Administration (CFDA), as well as summaries of biosimilar approvals in Uruguay and Paraguay. Other subjects of interest included naming for biosimilars in the US, the interchangeability of EU biosimilars, Federal purchases of biologicals for cancer in Brazil. Finally, how patent litigation creates barriers to US biosimilar market growth and how competition from biosimilars drives price reductions for biologicals in France was also of interest to readers.

Fresh partnerships announced for ranibizumab and trastuzumab biosimilars

Home/Pharma News | Posted 21/01/2022

Prestige BioPharma has partnered with Dr Reddy’s Laboratories (Dr Reddy’s) to commercialize their trastuzumab biosimilar, HD201, while MS Pharma has joined up with Formycon for the commercialization of its ranibizumab biosimilar, FYB201.

Spinoff updates: Merck’s Organon and Novartis’ Sandoz

Home/Pharma News | Posted 26/11/2021

Merck spinoff Organon has announced third quarter revenue of US$1.6 billion in 2021. This shows slight decline in women’s health medications but growth in biosimilar sales. Following its 2021 third quarter review, Novartis is considering the spinoff of its biosimilar division, Sandoz, as a standalone company.

Swiss Social Democrat’s for nationalization of Sandoz

Home/Pharma News | Posted 19/11/2021

In November 2021, the Social Democratic party in Switzerland urged the government to buy Novartis AG’s generics and biosimilars unit, Sandoz. 

Biocon Biologics and Serum Institute Life Sciences partnership

Home/Pharma News | Posted 12/11/2021

On 16 September 2021, a strategic partnership was announced between India-based biologicals specialist Biocon Biologics Limited (BBL), and Indian vaccine manufacturer Serum Institute Life Sciences (SILS), a subsidiary of Serum Institute of India Pvt Ltd.

Ustekinumab biosimilars: new international biopharma agreements

Home/Pharma News | Posted 12/11/2021

September and October 2021 saw new international agreements between biopharmaceutical companies regarding ustekinumab biosimilars. These were formed between BioFactura and Rani Therapeutics in the US, and China’s Bio-Thera Solutions and Pharmapark in Russia. 

Agreement to produce similar biotherapeutic product in Turkey

Home/Pharma News | Posted 05/11/2021

On 22 October 2021, an important agreement was signed between Nobel Pharmaceuticals and the IBG-OzBio partnership for the manufacturing of a similar biotherapeutic product in Turkey. This hopes to be a springboard for further collaborations and medicinal product development in the country. 

Collaborations to commercialize oncology biosimilars

Home/Pharma News | Posted 22/10/2021

New collaborations to commercialize oncology biosimilars have been announced between Sandoz and Bio-Thera Solutions, and between Innovent Biologics and Ascentage Pharma.

Licensing agreements signed for ustekinumab biosimilars

Home/Pharma News | Posted 17/09/2021

Bio-Thera Solutions have signed an exclusive commercialization and licensing agreement with Hikma Pharmaceuticals for the ustekinumab (Stelara) biosimilar BAT2206, similar to an agreement reached between Meiji Seika Pharma, Dong-A ST and Intas Pharmaceuticals.

Oncogen–BrightGene partnership

Home/Pharma News | Posted 10/09/2021

In June 2021, Malaysian oncology generics company, Oncogen, and China’s BrightGene Bio-Medical Technology announced that they are partnering to develop, manufacture, market and distribute generic drug products for the US market.